|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
TW321649B
(en)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
WO1996033977A1
(en)
*
|
1995-04-27 |
1996-10-31 |
Zeneca Limited |
Quinazoline derivatives
|
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
BR9707495A
(en)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Quinazoline derivative process for the preparation of the same pharmaceutical composition and process for the production of an antiangiogenic effect and / or reduction of vascular permeability in a warm-blooded animal
|
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
AU719327B2
(en)
|
1996-03-05 |
2000-05-04 |
Astrazeneca Ab |
4-anilinoquinazoline derivatives
|
|
NZ332119A
(en)
|
1996-04-12 |
2001-08-31 |
Warner Lambert Co |
Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
|
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
BR9709959A
(en)
*
|
1996-06-24 |
2000-05-09 |
Pfizer |
Tricyclic derivatives of substituted phenylamino for the treatment of hyperproliferative diseases
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
|
EP0837063A1
(en)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
US6090096A
(en)
|
1997-04-23 |
2000-07-18 |
Heartport, Inc. |
Antegrade cardioplegia catheter and method
|
|
DE19743435A1
(en)
|
1997-10-01 |
1999-04-08 |
Merck Patent Gmbh |
Benzamidine derivatives
|
|
MEP42008A
(en)
*
|
1998-04-29 |
2011-02-10 |
Osi Farmaceuticals Inc |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
US6384223B1
(en)
|
1998-07-30 |
2002-05-07 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
|
EE200100097A
(en)
|
1998-08-18 |
2002-06-17 |
The Regents Of The University Of California |
Inhibition of airway mucus production by administration of EGF-R antagonists
|
|
JP3270834B2
(en)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
Heteroaromatic bicyclic derivatives useful as anticancer agents
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
RS49836B
(en)
*
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
PROCEDURES AND INTERMEDIATES FOR OBTAINING ANTI-CANCIN UNITS
|
|
MXPA01012899A
(en)
|
1999-06-21 |
2002-07-30 |
Boehringer Ingelheim Pharma |
Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof.
|
|
WO2001004111A1
(en)
*
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
GB9922173D0
(en)
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
|
CN1391561A
(en)
*
|
1999-09-21 |
2003-01-15 |
阿斯特拉曾尼卡有限公司 |
Quinazoline compounds and pharmaceutical compositions containing them
|
|
GB9925958D0
(en)
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
|
PL203782B1
(en)
|
1999-11-05 |
2009-11-30 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
|
UA74803C2
(en)
*
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
CA2403365A1
(en)
|
2000-04-07 |
2001-10-18 |
Astrazeneca Ab |
Quinazoline compounds
|
|
UA73993C2
(en)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
|
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
|
MXPA03001332A
(en)
|
2000-08-21 |
2004-07-08 |
Astrazeneca Ab |
Quinazoline derivatives.
|
|
EP1415987B1
(en)
|
2000-10-20 |
2007-02-28 |
Eisai R&D Management Co., Ltd. |
Nitrogenous aromatic ring compounds as anti cancer agents
|
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
|
DE60144284D1
(en)
|
2000-11-01 |
2011-05-05 |
Millennium Pharm Inc |
NITROGENIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
EP1363627A2
(en)
|
2001-02-19 |
2003-11-26 |
Novartis AG |
Treatment of solid tumours with rapamycin derivatives
|
|
JP2002293773A
(en)
*
|
2001-03-30 |
2002-10-09 |
Sumika Fine Chemicals Co Ltd |
Method for producing quinazoline derivative
|
|
RU2332415C2
(en)
*
|
2001-04-27 |
2008-08-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Pyrazole derivatives, useful as inhibitors of protein kinase
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
WO2003074529A2
(en)
|
2002-03-01 |
2003-09-12 |
Pfizer Inc. |
iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
|
|
US7078409B2
(en)
|
2002-03-28 |
2006-07-18 |
Beta Pharma, Inc. |
Fused quinazoline derivatives useful as tyrosine kinase inhibitors
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
DE10221018A1
(en)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
|
|
AU2003240655B2
(en)
|
2002-05-16 |
2007-09-06 |
Novartis Ag |
Use of EDG receptor binding agents in cancer
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
ES2376165T3
(en)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4.
|
|
EP3321282A1
(en)
|
2002-09-27 |
2018-05-16 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
|
WO2004046101A2
(en)
|
2002-11-20 |
2004-06-03 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
|
|
US20060167026A1
(en)
*
|
2003-01-06 |
2006-07-27 |
Hiroyuki Nawa |
Antipsychotic molecular-targeting epithelial growth factor receptor
|
|
GB0302882D0
(en)
*
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
|
US7148231B2
(en)
*
|
2003-02-17 |
2006-12-12 |
Hoffmann-La Roche Inc. |
[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
|
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
PA8595001A1
(en)
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
|
|
ATE508747T1
(en)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-KIT KINASE INHIBITORS
|
|
CA2522522A1
(en)
*
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Quinazoline compounds
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
EP2644195A1
(en)
|
2003-05-19 |
2013-10-02 |
Irm Llc |
Immunosuppressant Compounds and Compositions
|
|
JP4724657B2
(en)
|
2003-05-30 |
2011-07-13 |
アストラゼネカ ユーケー リミテッド |
process
|
|
WO2005001053A2
(en)
|
2003-06-09 |
2005-01-06 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
|
PL1680426T3
(en)
|
2003-06-10 |
2008-02-29 |
Hoffmann La Roche |
1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
|
|
CN1984660B
(en)
|
2003-07-03 |
2010-12-15 |
美瑞德生物工程公司 |
4-Arylamino-quinazolines as caspase-specific activators and inducers of apoptosis
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
WO2005016346A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Array Biopharma Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
SG135193A1
(en)
*
|
2003-08-18 |
2007-09-28 |
Pfizer Prod Inc |
Dosing schedule for erbb2 anticancer agents
|
|
CA2536321A1
(en)
|
2003-08-29 |
2005-03-10 |
Pfizer Inc. |
Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
|
|
ES2305844T3
(en)
|
2003-09-16 |
2008-11-01 |
Astrazeneca Ab |
DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE.
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
DE10349113A1
(en)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Process for the preparation of aminocrotonyl compounds
|
|
NZ547633A
(en)
|
2003-11-06 |
2010-08-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2005044788A1
(en)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
Urea derivative and process for producing the same
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
BRPI0418102A
(en)
|
2003-12-23 |
2007-04-27 |
Pfizer |
quinoline derivatives
|
|
ES2315834T3
(en)
|
2004-02-03 |
2009-04-01 |
Astrazeneca Ab |
DERIVATIVES OF QUINAZOLINA.
|
|
JP4934432B2
(en)
|
2004-02-19 |
2012-05-16 |
レクサン ファーマシューティカルズ インコーポレイテッド |
Quinazoline derivatives and therapeutic use of quinazoline derivatives
|
|
JP4734319B2
(en)
|
2004-03-19 |
2011-07-27 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
Human anti-epidermal growth factor receptor antibody
|
|
ES2741546T3
(en)
|
2004-03-31 |
2020-02-11 |
Massachusetts Gen Hospital |
Method to determine the response of cancer to treatments directed at the epidermal growth factor receptor
|
|
BRPI0509721A
(en)
|
2004-04-07 |
2007-09-25 |
Novartis Ag |
iap inhibitors
|
|
BRPI0510717B8
(en)
|
2004-05-06 |
2021-05-25 |
Bioresponse Llc |
use of 3,3'-diindolylmethane (dim) or 2-(indol-3-ylmethyl)-3,3'-diindolylmethane (ltr)
|
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
|
SI2471813T1
(en)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
AU2005283422C1
(en)
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
|
KR101270829B1
(en)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
Cystein engineered antibodies and conjugates
|
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
DE602005026865D1
(en)
|
2004-12-14 |
2011-04-21 |
Astrazeneca Ab |
PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUM-MEANS
|
|
PE20060777A1
(en)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
|
|
ATE497762T1
(en)
|
2004-12-30 |
2011-02-15 |
Bioresponse Llc |
USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF DISEASES RELATED TO THE RESPIRATORY SYNCYTIAL VIRUS
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
US7625911B2
(en)
|
2005-01-12 |
2009-12-01 |
Mai De Ltd. |
Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
|
|
BRPI0518104B8
(en)
|
2005-01-21 |
2021-05-25 |
Genentech Inc |
industrialized article and use of her2 antibody
|
|
CN101146532B
(en)
|
2005-01-21 |
2012-05-09 |
阿斯泰克斯治疗有限公司 |
Pharmaceutical compounds
|
|
GB0501999D0
(en)
*
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
RU2404806C2
(en)
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
|
|
KR100910333B1
(en)
*
|
2005-02-23 |
2009-07-31 |
시오노기세이야쿠가부시키가이샤 |
Quinazoline derivative having tyrosine kinase inhibitory activity
|
|
JP5054544B2
(en)
|
2005-02-26 |
2012-10-24 |
アストラゼネカ アクチボラグ |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
CN101163468A
(en)
|
2005-02-28 |
2008-04-16 |
卫材R&D管理有限公司 |
Novel combination of sulfonamide compounds
|
|
AU2006235487B2
(en)
*
|
2005-04-12 |
2011-12-22 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
|
CN1854130B
(en)
*
|
2005-04-15 |
2011-04-20 |
中国医学科学院药物研究所 |
Chinazoline derivative, its production, medicinal composition and use
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CA2680945C
(en)
|
2005-06-17 |
2014-03-18 |
Imclone Systems Incorporated |
Anti-pdgfralpha antibodies
|
|
EP2004695A2
(en)
|
2005-07-08 |
2008-12-24 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
|
US8129114B2
(en)
|
2005-08-24 |
2012-03-06 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
|
DE602006018331D1
(en)
|
2005-09-20 |
2010-12-30 |
Astrazeneca Ab |
4- (1H-INDAZOL-5-YLAMINO) CHINAZOLINE COMPOUNDS AS INHIBITORS OF ERBB RECEPTORT ROSINKINASE FOR THE TREATMENT OF CANCER
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
|
CA2833706C
(en)
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
|
ES2481671T3
(en)
|
2005-11-21 |
2014-07-31 |
Novartis Ag |
MTOR inhibitors in the treatment of endocrine tumors
|
|
WO2007060691A2
(en)
*
|
2005-11-23 |
2007-05-31 |
Natco Pharma Limited |
A novel process for the preparation of erlotinib
|
|
RU2384331C2
(en)
*
|
2005-12-05 |
2010-03-20 |
Пфайзер Продактс Инк. |
Method of treating abnormal cell expansion
|
|
CN101003514A
(en)
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
Derivative of quinazoline, preparation method and usage
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
PI-3 Kinase inhibitors and methods of their use
|
|
WO2007092453A2
(en)
|
2006-02-03 |
2007-08-16 |
Imclone Systems Incorporated |
Igf-ir antagonists as adjuvants for treatment of prostate cancer
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
MX2008012715A
(en)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer.
|
|
AU2007234382B2
(en)
|
2006-04-05 |
2011-06-09 |
Novartis Ag |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
|
AR060358A1
(en)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
QUINAZOLINS FOR THE INHIBITION OF PDK 1
|
|
KR20080110912A
(en)
|
2006-04-19 |
2008-12-19 |
노파르티스 아게 |
Inhibition method of indazole compound and CD7
|
|
MX2008014292A
(en)
|
2006-05-09 |
2008-11-18 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof.
|
|
WO2007136103A1
(en)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
WO2007138613A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Vittal Mallya Scientific Research Foundation |
A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
|
|
WO2007138612A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Vittal Mallya Scientific Research Foundation |
A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride
|
|
CN101547910A
(en)
|
2006-07-28 |
2009-09-30 |
合成纤维有限公司 |
Crystalline Erlotinib
|
|
US8524867B2
(en)
|
2006-08-14 |
2013-09-03 |
Xencor, Inc. |
Optimized antibodies that target CD19
|
|
WO2008026748A1
(en)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
ATE522625T1
(en)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING PDGFRA, KIT OR KDG GENE AS GENETIC MARKERS
|
|
RU2492864C2
(en)
|
2006-09-18 |
2013-09-20 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Method of treating cancer carrying egfr mutations
|
|
EP2081933B1
(en)
|
2006-09-29 |
2011-03-23 |
Novartis AG |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
|
KR101129868B1
(en)
|
2006-10-04 |
2012-04-12 |
화이자 프로덕츠 인코포레이티드 |
Pyrido[4,3-d]pyrimidin-43h-one derivatives as calcium receptor antagonists
|
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8372856B2
(en)
*
|
2006-10-27 |
2013-02-12 |
Synthon Bv |
Hydrates of erlotinib hydrochloride
|
|
BRPI0717753B1
(en)
|
2006-10-27 |
2022-04-12 |
Bioresponse, Llc |
Use of a composition comprising 50-250 mg of one or more dim-related indoles and one or more anti-protozoal agents, and, composition
|
|
EP1921070A1
(en)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
|
|
US8343950B2
(en)
*
|
2006-12-15 |
2013-01-01 |
Concert Pharmaceuticals, Inc. |
Quinazoline derivatives and methods of treatment
|
|
EP2116246A1
(en)
|
2007-01-19 |
2009-11-11 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
|
US7998949B2
(en)
|
2007-02-06 |
2011-08-16 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
|
CN101245050A
(en)
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-aniline quinazoline derivative salt
|
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
WO2008102369A1
(en)
|
2007-02-21 |
2008-08-28 |
Natco Pharma Limited |
Novel polymorphs of erlotinib hydrochloride and method of preparation
|
|
CA2677108A1
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
KR20140069232A
(en)
|
2007-04-04 |
2014-06-09 |
시플라 리미티드 |
Process for preparation of erlotinib and its pharmaceutically acceptable salts
|
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
|
WO2008154249A2
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
MX2010000617A
(en)
|
2007-07-17 |
2010-05-17 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor.
|
|
WO2009030224A2
(en)
*
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Novel quinazoline compounds and the use thereof for treating cancerous diseases
|
|
CA2703767A1
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
CL2008003449A1
(en)
|
2007-11-21 |
2010-02-19 |
Imclone Llc |
Antibody or fragments thereof against the macrophage / rum stimulating protein receptor; pharmaceutical composition comprising it; use to inhibit angiogenesis, tumor growth, proliferation, migration and invasion of tumor cells, activation of rum or phosphorylation of mapk and / or akt; and use to treat cancer.
|
|
UY31545A1
(en)
|
2007-12-20 |
2009-08-03 |
|
NEW DERIVATIVES OF 2-CARBOXAMIDE CIANOAMINOUREA, ITS SALTS AND PHARMACEUTICALLY ACCEPTABLE PROFARMS, PREPARATION PROCESSES AND APPLICATIONS
|
|
DK2808343T3
(en)
|
2007-12-26 |
2019-08-19 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
|
AU2008347940A1
(en)
|
2008-01-18 |
2009-07-23 |
Natco Pharma Limited |
6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
|
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
|
BRPI0907916A2
(en)
|
2008-02-07 |
2015-07-28 |
Boehringer Ingelheim Int |
Spirocycle heterocycles, medicaments containing such compounds, and processes for preparing them
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
KR101673621B1
(en)
|
2008-03-24 |
2016-11-07 |
노파르티스 아게 |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
CN101544609A
(en)
|
2008-03-25 |
2009-09-30 |
上海艾力斯医药科技有限公司 |
Crystallization form of 4-anilinoquinazoline derivatives
|
|
ES2519474T3
(en)
|
2008-03-26 |
2014-11-07 |
Novartis Ag |
Hydroxamate-based deacetylase B inhibitors
|
|
US20090269354A1
(en)
*
|
2008-03-28 |
2009-10-29 |
Concert Pharmaceuticals, Inc. |
Quinazoline derivatives and methods of treatment
|
|
WO2009138781A1
(en)
|
2008-05-13 |
2009-11-19 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
|
|
ES2430590T3
(en)
|
2008-05-14 |
2013-11-21 |
Genomic Health, Inc. |
Predictors of patient response to treatment with EGF receptor inhibitors
|
|
CN101584696A
(en)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
Composition containing quinazoline derivatives, preparation method and use
|
|
DE102008031039A1
(en)
|
2008-06-30 |
2009-12-31 |
Dömling, Alexander, Priv.-Doz. Dr. |
Use of N-phenylquinazolin-4-amine derivatives as receptor tyrosine kinase inhibitor for accompanying treatment of organ transplantations
|
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
ES2704986T3
(en)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
|
|
MX2011004824A
(en)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
USE OF CATHOLIC BUTANE DERIVATIVES IN THERAPY AGAINST CANCER.
|
|
MX2011005002A
(en)
|
2008-11-11 |
2011-05-25 |
Lilly Co Eli |
P70 s6 kinase inhibitor and egfr inhibitor combination therapy.
|
|
HRP20131106T1
(en)
|
2008-12-18 |
2013-12-20 |
Novartis Ag |
HEMIFUMARATE SALT OF 1- [4- [1- (4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO) -ETHYL] -2-ETHYL-BENZYL] -AZETIDINE-3-CARBOXYLIC ACIDS
|
|
CN102256941A
(en)
|
2008-12-18 |
2011-11-23 |
诺瓦提斯公司 |
new salt
|
|
AU2009327405A1
(en)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
|
EP2213281A1
(en)
|
2009-02-02 |
2010-08-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010107968A1
(en)
|
2009-03-18 |
2010-09-23 |
Osi Pharmaceuticals, Inc. |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
EP2411373B1
(en)
*
|
2009-03-26 |
2015-10-21 |
Ranbaxy Laboratories Limited |
Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
|
|
KR101360725B1
(en)
|
2009-06-26 |
2014-02-07 |
노파르티스 아게 |
1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp17
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
LT2451445T
(en)
|
2009-07-06 |
2019-06-25 |
Boehringer Ingelheim International Gmbh |
Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
|
US9050341B2
(en)
*
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(en)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION
|
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
ES2564797T3
(en)
|
2009-08-19 |
2016-03-29 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition containing a quinoline derivative
|
|
EA201200318A1
(en)
|
2009-08-20 |
2012-09-28 |
Новартис Аг |
Heterocyclic oximes
|
|
JP2013503129A
(en)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
Tetra-substituted heteroaryl compounds and their use as MDM2 and / or MDM4 modulators
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US20120220594A1
(en)
|
2009-10-30 |
2012-08-30 |
Bristol-Meyers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
EP2496575B1
(en)
|
2009-11-04 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
|
WO2011058164A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2011069104A2
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
ES2484171T3
(en)
|
2009-12-08 |
2014-08-11 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
|
EP2348020A1
(en)
|
2009-12-23 |
2011-07-27 |
Esteve Química, S.A. |
Preparation process of erlotinib
|
|
WO2011086053A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
AU2011222867B2
(en)
|
2010-03-04 |
2014-03-06 |
Annika Algars |
Method for selecting patients for treatment with an EGFR inhibitor
|
|
RU2012141536A
(en)
|
2010-03-17 |
2014-04-27 |
Ф. Хоффманн-Ля Рош Аг |
IMIDAZOPYRIDINES, COMPOSITIONS AND METHODS OF APPLICATION
|
|
CA2794708C
(en)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
|
CN103038643A
(en)
|
2010-04-16 |
2013-04-10 |
基因泰克公司 |
FOXO3A as a predictive biomarker of PI3K/AKT kinase pathway inhibitor potency
|
|
DE202010006543U1
(en)
|
2010-05-07 |
2010-09-09 |
Ratiopharm Gmbh |
Erlotinibresinat
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
BR112012028964A2
(en)
|
2010-05-21 |
2016-07-26 |
Shanghai Inst Pharm Industry |
polycyclic quinazolines, their method of preparation and their uses
|
|
WO2011147102A1
(en)
*
|
2010-05-28 |
2011-12-01 |
翔真生物科技股份有限公司 |
Synthetic method for 6,7-substituents-4-aniline quinazoline
|
|
RU2560683C2
(en)
|
2010-06-25 |
2015-08-20 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Anticancer agent involving combinations of kinase inhibitory compounds
|
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
|
NZ606042A
(en)
*
|
2010-07-23 |
2015-05-29 |
Generics Uk Ltd |
Process for the preparation of erlotinib and salts thereof
|
|
AR082418A1
(en)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO
|
|
BR112013006016A2
(en)
|
2010-09-15 |
2016-06-07 |
Hoffmann La Roche |
azabenzothiazole compounds, compositions and methods of use
|
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
|
IT1402029B1
(en)
|
2010-10-14 |
2013-08-28 |
Italiana Sint Spa |
PROCEDURE FOR THE PREPARATION OF ERLOTINIB
|
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES AGAINST THE MARKER 8 TUMOR ENDOTHELIAL
|
|
BR112013011520A2
(en)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pyrazolo pyridines and pyrazolo pyridines and their use as tyk2 inhibitors
|
|
KR20130105675A
(en)
*
|
2010-11-25 |
2013-09-25 |
라티오팜 게엠베하 |
New Salts and Polymorphs of Afatinib
|
|
DE102010053124A1
(en)
|
2010-12-01 |
2012-06-06 |
Volkswagen Ag |
Clutch, particularly for transmission of motor vehicle, particularly dual clutch for automatic or automated dual clutch transmission, has friction clutch, which is connected with motor shaft on one side
|
|
MX2013007336A
(en)
|
2010-12-21 |
2013-08-01 |
Novartis Ag |
Bi-heteroaryl compounds as vps34 inhibitors.
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
PL2670753T3
(en)
|
2011-01-31 |
2017-05-31 |
Novartis Ag |
Novel heterocyclic derivatives
|
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
WO2012122058A2
(en)
|
2011-03-04 |
2012-09-13 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
JP5832559B2
(en)
|
2011-03-10 |
2015-12-16 |
オメロス コーポレーション |
Generation of anti-FN14 monoclonal antibodies by accelerated antibody evolution ex vivo
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
MX2013009931A
(en)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Therapeutic agent for tumor.
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
WO2012149413A1
(en)
|
2011-04-28 |
2012-11-01 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
CN102918029B
(en)
*
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
|
|
ES2705950T3
(en)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
|
|
KR20140034898A
(en)
|
2011-06-09 |
2014-03-20 |
노파르티스 아게 |
Heterocyclic sulfonamide derivatives
|
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
|
CN102267952B
(en)
*
|
2011-06-21 |
2013-12-11 |
天津市汉康医药生物技术有限公司 |
Quinazoline compound and preparation method and application thereof
|
|
SG195067A1
(en)
|
2011-06-27 |
2013-12-30 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
US8575339B2
(en)
*
|
2011-07-05 |
2013-11-05 |
Xueheng Cheng |
Derivatives of erlotinib
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
EP2742067A4
(en)
|
2011-08-12 |
2015-03-04 |
Omeros Corp |
ANTI-FZD10 MONOCLONAL ANTIBODIES AND METHODS OF USE
|
|
CA2843499A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
|
US12194002B2
(en)
|
2011-08-17 |
2025-01-14 |
Dennis Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
|
|
RU2614254C2
(en)
|
2011-08-31 |
2017-03-24 |
Дженентек, Инк. |
Diagnostic markers
|
|
EA026655B1
(en)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS c-Met TYROSINE KINASE INHIBITORS
|
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
MX2014003698A
(en)
|
2011-09-30 |
2014-07-28 |
Genentech Inc |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells.
|
|
HU230483B1
(en)
|
2011-10-10 |
2016-07-28 |
Egis Gyógyszergyár Nyrt. |
Erlotinib salts
|
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
PT2771342T
(en)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Purine derivatives and their use in the treatment of disease
|
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
LT2794600T
(en)
|
2011-12-22 |
2018-02-26 |
Novartis Ag |
2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
KR20140104047A
(en)
|
2011-12-23 |
2014-08-27 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
EA201491268A1
(en)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF BCL2 WITH PARTNERS ON THE LINKAGE
|
|
EA201491259A1
(en)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF BCL2 WITH BOND PARTNERS
|
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
EA201491265A1
(en)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL-2 WITH PARTNERS ON BINDING
|
|
UY34591A
(en)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
IMIDAZOPIRROLIDINONA COMPOUNDS
|
|
CA2866612C
(en)
|
2012-03-08 |
2018-01-16 |
Halozyme, Inc. |
Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
|
|
CN104220457A
(en)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
Diagnosis and treatment involving HER3 inhibitors
|
|
US20150297604A1
(en)
|
2012-04-03 |
2015-10-22 |
Novartis Ag |
Combination Products with Tyrosine Kinase Inhibitors and their Use
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
|
WO2013175417A1
(en)
|
2012-05-24 |
2013-11-28 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
WO2014037961A1
(en)
|
2012-09-04 |
2014-03-13 |
Shilpa Medicare Limited |
Crystalline erlotinib hydrochloride process
|
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
|
WO2014098176A1
(en)
|
2012-12-21 |
2014-06-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Amorphous form of quinoline derivative, and method for producing same
|
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
WO2014118112A1
(en)
|
2013-01-29 |
2014-08-07 |
Synthon B.V. |
Pharmaceutical composition comprising erlotinib hydrochloride
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
WO2014134202A1
(en)
|
2013-02-26 |
2014-09-04 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
BR112015022545A2
(en)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
pyrazole compounds and the uses thereof
|
|
CN105246482A
(en)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
Combinations of kinase inhibitors and uses thereof
|
|
US20160051556A1
(en)
|
2013-03-21 |
2016-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
|
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
|
RU2658601C2
(en)
|
2013-05-14 |
2018-06-21 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
MX2016002794A
(en)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Antiproliferative compounds.
|
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
CA2922562A1
(en)
|
2013-09-12 |
2015-03-19 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
AR097661A1
(en)
|
2013-09-17 |
2016-04-06 |
Obi Pharma Inc |
COMPOSITIONS OF A CARBOHYDRATE VACCINE TO INDUCE IMMUNE RESPONSES AND THEIR USES IN CANCER TREATMENT
|
|
AU2014321419B2
(en)
|
2013-09-22 |
2017-06-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
TW201605857A
(en)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Therapeutic inhibitors of CDK8 and uses thereof
|
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
|
MX378409B
(en)
|
2013-12-06 |
2025-03-10 |
Novartis Ag |
DOSAGE REGIMEN FOR AN ALPHA-ISOMORPHIC SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR.
|
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
|
CA2933883A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
EP3122729A4
(en)
|
2014-03-28 |
2017-11-15 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
|
CN106103486B
(en)
|
2014-03-31 |
2020-04-21 |
豪夫迈·罗氏有限公司 |
Anti-OX40 antibodies and methods of use
|
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
|
RU2016140160A
(en)
|
2014-04-03 |
2018-05-07 |
Инвиктус Онколоджи Пвт. Лтд. |
SUPRAMOLECULAR COMBINATOR MEDICINES
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
JP6526789B2
(en)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
Combination therapy
|
|
ES2926687T3
(en)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Highly pure quinoline derivative and method for its production
|
|
CN107074823B
(en)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
Therapeutic compounds and their uses
|
|
JP2017529358A
(en)
|
2014-09-19 |
2017-10-05 |
ジェネンテック， インコーポレイテッド |
Use of CBP / EP300 inhibitors and BET inhibitors for the treatment of cancer
|
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
EP3206717B1
(en)
|
2014-10-17 |
2020-11-25 |
Novartis AG |
Combination of ceritinib with an egfr inhibitor
|
|
CA2908441A1
(en)
|
2014-10-28 |
2016-04-28 |
Cerbios-Pharma Sa |
Process for the preparation of erlotinib
|
|
CN106796235B
(en)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
Assays for detecting T cell immune subsets and methods of use thereof
|
|
MX2017005751A
(en)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment.
|
|
BR112017008628A2
(en)
|
2014-11-06 |
2018-01-30 |
Genentech Inc |
combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
MA40940A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
|
MA40943A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
CA2967368A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CN107531690B
(en)
|
2014-11-27 |
2020-11-06 |
基因泰克公司 |
4,5,6,7-Tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-amine compounds useful as CBP and/or EP300 inhibitors
|
|
WO2016082879A1
(en)
*
|
2014-11-27 |
2016-06-02 |
Synthon B.V. |
Pharmaceutical composition comprising erlotinib hydrochloride
|
|
WO2016106340A2
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
|
CN107223163A
(en)
|
2014-12-24 |
2017-09-29 |
豪夫迈·罗氏有限公司 |
Methods for treatment, diagnosis and prognosis of bladder cancer
|
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
|
WO2016112284A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
JP6659703B2
(en)
|
2015-01-09 |
2020-03-04 |
ジェネンテック， インコーポレイテッド |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
RS65049B1
(en)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
|
MA41598A
(en)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
|
|
CN104725327B
(en)
*
|
2015-03-03 |
2017-08-25 |
山东大学 |
A kind of environment-friendly preparation method of erlotinib Hydrochloride
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
MX2017012805A
(en)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Antigen binding complex having agonistic activity and methods of use.
|
|
AU2016262074A1
(en)
|
2015-05-12 |
2017-11-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
MX392671B
(en)
|
2015-05-29 |
2025-03-24 |
Genentech Inc |
PD-L1-BINDING ANTAGONISTS AND THEIR USES FOR CANCER TREATMENT
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
KR20180025888A
(en)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
Methods for treating cancer using anti-OX40 antibodies and PD-1 axis-binding antagonists
|
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
|
KR102689256B1
(en)
|
2015-06-17 |
2024-07-30 |
제넨테크, 인크. |
Methods for treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes
|
|
CN105017162B
(en)
*
|
2015-06-26 |
2017-10-27 |
陕西师范大学 |
4 pairs of propenylbenzene amido quinazoline derivatives and its application in antineoplastic is prepared
|
|
ES2887426T3
(en)
|
2015-08-20 |
2021-12-22 |
Eisai R&D Man Co Ltd |
Lenvatinib combined with etoposide and ifosfamide for use in treating a tumor
|
|
ES2862727T3
(en)
|
2015-08-26 |
2021-10-07 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Fused tricyclic compounds as protein kinase inhibitors
|
|
ES2761885T3
(en)
|
2015-08-28 |
2020-05-21 |
Novartis Ag |
Pharmaceutical combinations comprising (a) cyclin-dependent kinase inhibitor 4/6 (CDK4 / 6) LEE011 (= ribociclib) and (b) epidermal growth factor receptor (EGFR) inhibitor erlotinib, for the treatment or cancer prevention
|
|
HK1256912A1
(en)
|
2015-09-04 |
2019-10-04 |
台湾浩鼎生技股份有限公司 |
Glycan arrays and method of use
|
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
|
NZ739750A
(en)
|
2015-09-25 |
2019-11-29 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
JP2018532750A
(en)
|
2015-11-02 |
2018-11-08 |
ノバルティス アーゲー |
Dosage regimen of phosphatidylinositol 3-kinase inhibitor
|
|
AU2016369528B2
(en)
|
2015-12-16 |
2021-04-22 |
Genentech, Inc. |
Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
|
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
EP4155415A1
(en)
|
2016-02-29 |
2023-03-29 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
TWI780045B
(en)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
Antibodies, pharmaceutical compositions and methods
|
|
KR20180134347A
(en)
|
2016-04-15 |
2018-12-18 |
제넨테크, 인크. |
Diagnosis and Treatment of Cancer
|
|
PL3443350T3
(en)
|
2016-04-15 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Methods of monitoring and treating cancer
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
RU2018140976A
(en)
|
2016-04-22 |
2020-05-22 |
Оби Фарма, Инк. |
CANCER IMMUNOTHERAPY BY IMMUNE ACTIVATION OR IMMUNE MODULATION THROUGH GLOBO SERIES ANTIGENS
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
MA45146A
(en)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER
|
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US20200129519A1
(en)
|
2016-06-08 |
2020-04-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP4371570A3
(en)
|
2016-06-08 |
2024-07-17 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
|
US11642400B2
(en)
|
2016-07-27 |
2023-05-09 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
|
KR102528998B1
(en)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
Human Antibodies, Pharmaceutical Compositions and Methods
|
|
JP2019530434A
(en)
|
2016-08-05 |
2019-10-24 |
ジェネンテック， インコーポレイテッド |
Multivalent and multi-epitope antibodies with agonist activity and methods of use
|
|
CN109476748B
(en)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
Methods for the treatment and diagnosis of cancer
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CN110418851A
(en)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
The treatment of cancer and diagnostic method
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
CN110267678A
(en)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
Anti-MIC antibodies and methods of use
|
|
KR20190077103A
(en)
|
2016-11-21 |
2019-07-02 |
오비아이 파머 인코퍼레이티드 |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
KR20230150408A
(en)
|
2016-12-22 |
2023-10-30 |
암젠 인크 |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
JP6581320B2
(en)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Pharmaceutical composition for tumor treatment
|
|
AU2018228873A1
(en)
|
2017-03-01 |
2019-08-29 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CN106928069B
(en)
*
|
2017-03-21 |
2019-03-19 |
上海玉函化工有限公司 |
A kind of preparation method of 4,5- bis- (2- methoxy ethoxy) -2- ethyl nitrobenzoate
|
|
BR112019021411A2
(en)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
methods to treat or slow the progression of cancer and to improve function, uses of an immunoconjugate, an agonist, an antagonist, compositions, kit and invention
|
|
RU2019134940A
(en)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
TREATMENT OF HEPATOCELLULAR CARCINOMA
|
|
JOP20190272A1
(en)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
CN107200715B
(en)
*
|
2017-06-22 |
2020-05-29 |
陕西师范大学 |
Quinazoline derivatives and their application in the preparation of antitumor drugs
|
|
IL271888B2
(en)
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
AU2018316343B2
(en)
|
2017-08-11 |
2025-06-12 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
JP7530829B2
(en)
|
2017-09-08 |
2024-08-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Cancer diagnosis and treatment methods
|
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
US20200290978A1
(en)
*
|
2017-09-26 |
2020-09-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting avil expression
|
|
KR20200075860A
(en)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
How to diagnose and treat cancer
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
SG11202006441SA
(en)
|
2018-01-15 |
2020-08-28 |
Epiaxis Therapeutics Pty Ltd |
Agents and methods for predicting response to therapy
|
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
US11673897B2
(en)
|
2018-01-26 |
2023-06-13 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
CR20200355A
(en)
|
2018-01-26 |
2021-02-22 |
Exelixis Inc |
COMPOUNDS FOR THE TREATMENT OF KINE-DEPENDENT DISORDERS
|
|
SMT202500395T1
(en)
|
2018-01-26 |
2025-11-10 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
TWI660728B
(en)
*
|
2018-02-09 |
2019-06-01 |
國立交通大學 |
Quinazolinamine derivatives and pharmaceutical compositions and uses thereof
|
|
JP7391027B2
(en)
|
2018-02-26 |
2023-12-04 |
ジェネンテック， インコーポレイテッド |
Medication for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
|
AU2019262599B2
(en)
|
2018-05-04 |
2023-10-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MA52501A
(en)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
|
|
MA52564A
(en)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
KRAS G12C INHIBITORS FOR CANCER TREATMENT
|
|
AU2019275404A1
(en)
|
2018-05-21 |
2020-12-03 |
Bruker Spatial Biology, Inc. |
Molecular gene signatures and methods of using same
|
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
|
JP7399895B2
(en)
|
2018-06-23 |
2023-12-18 |
ジェネンテック， インコーポレイテッド |
Method of treating lung cancer with PD-1 axis binding antagonists, platinum agents, and topoisomerase II inhibitors
|
|
CN110642796B
(en)
*
|
2018-06-27 |
2023-03-17 |
烟台药物研究所 |
Quinazoline derivative and application thereof
|
|
TW202504930A
(en)
|
2018-06-27 |
2025-02-01 |
台灣浩鼎生技股份有限公司 |
Glycosynthase variants for glycoprotein engineering and methods of use
|
|
BR112021000673A2
(en)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
methods for treating an individual with lung cancer, kits, anti-pd-l1 antibody and compositions
|
|
CN112805267B
(en)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
Formamide and sulfonamide derivatives used as TEAD modulators
|
|
CN112955747A
(en)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
Methods for treatment and diagnosis of bladder cancer
|
|
JP7475336B2
(en)
|
2018-09-21 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
Diagnostic methods for triple-negative breast cancer
|
|
MX2021003517A
(en)
|
2018-09-25 |
2021-08-16 |
Black Diamond Therapeutics Inc |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use.
|
|
JP2022512584A
(en)
|
2018-10-04 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
EGFR inhibitor for treating keratoderma
|
|
AU2019362972A1
(en)
|
2018-10-17 |
2021-05-20 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
JP7516029B2
(en)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
|
|
MX2021005700A
(en)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same.
|
|
JP7377679B2
(en)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
|
|
MX419368B
(en)
|
2018-12-20 |
2025-01-14 |
Amgen Inc |
Heteroaryl amides useful as kif18a inhibitors
|
|
EP3898592B1
(en)
|
2018-12-20 |
2024-10-09 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
KR102875569B1
(en)
|
2018-12-20 |
2025-10-23 |
암젠 인크 |
KIF18A inhibitor
|
|
CA3123042A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
|
|
CN113396230A
(en)
|
2019-02-08 |
2021-09-14 |
豪夫迈·罗氏有限公司 |
Methods of diagnosis and treatment of cancer
|
|
JP7520389B2
(en)
|
2019-02-27 |
2024-07-23 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
Methods and agents for assessing T cell function and predicting response to therapy - Patents.com
|
|
BR112021016923A2
(en)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Methods for treating a patient with hematologic cancer, methods for treating a patient with relapsed or refractory mm, methods for treating a patient having a relapsed or refractory lnh, and kits
|
|
CN113727758A
(en)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
Bicyclic heterocyclic compounds and use thereof
|
|
AU2020232242A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
MX2021013222A
(en)
|
2019-05-03 |
2022-01-06 |
Genentech Inc |
Methods of treating cancer with an anti-pd-l1 antibody.
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
CN112300279A
(en)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
Methods and compositions directed to anti-CD 73 antibodies and variants
|
|
AU2020324406A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
|
ES3051917T3
(en)
|
2019-08-02 |
2025-12-30 |
Amgen Inc |
Kif18a inhibitors
|
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
US20220281843A1
(en)
|
2019-08-02 |
2022-09-08 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3150701A1
(en)
|
2019-08-15 |
2021-02-18 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
TWI873176B
(en)
|
2019-09-04 |
2025-02-21 |
美商建南德克公司 |
Cd8 binding agents and uses thereof
|
|
JP2022551422A
(en)
|
2019-09-26 |
2022-12-09 |
エグゼリクシス， インコーポレイテッド |
Pyridone compounds and methods of use in modulating protein kinases
|
|
WO2021062085A1
(en)
|
2019-09-27 |
2021-04-01 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
|
EP4051674A1
(en)
|
2019-10-29 |
2022-09-07 |
F. Hoffmann-La Roche AG |
Bifunctional compounds for the treatment of cancer
|
|
BR112022008535A2
(en)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO TREAT CANCER AND A RAS PROTEIN DISORDER
|
|
WO2021091982A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN120699039A
(en)
|
2019-11-04 |
2025-09-26 |
锐新医药公司 |
RAS inhibitors
|
|
JP2022553803A
(en)
|
2019-11-06 |
2022-12-26 |
ジェネンテック， インコーポレイテッド |
Diagnostic and therapeutic methods for the treatment of blood cancers
|
|
US20210139517A1
(en)
|
2019-11-08 |
2021-05-13 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
WO2021094379A1
(en)
|
2019-11-12 |
2021-05-20 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
KR20220101138A
(en)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
Therapeutic compounds and methods of use
|
|
TW202532412A
(en)
|
2019-11-14 |
2025-08-16 |
美商安進公司 |
Improved synthesis of kras g12c inhibitor compound
|
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
|
JP2023505100A
(en)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
Covalent RAS inhibitors and uses thereof
|
|
PE20221511A1
(en)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
|
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
JP2023509701A
(en)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ，インコーポレイテッド |
SHP2 inhibitor dosing and methods of treating cancer
|
|
KR20220130190A
(en)
|
2020-01-20 |
2022-09-26 |
아스트라제네카 아베 |
Epidermal growth factor receptor tyrosine kinase inhibitor for cancer treatment
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods of treating cancer with an antibody to an anti-ti antagonist
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
JP2023520515A
(en)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
Therapeutic and diagnostic methods for cancer
|
|
CN115885050A
(en)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
|
KR20230042600A
(en)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Methods of Delaying, Preventing, and Treating Acquired Resistance to RAS Inhibitors
|
|
MX2022015881A
(en)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists.
|
|
EP4172628A1
(en)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
|
JP2023531305A
(en)
|
2020-06-30 |
2023-07-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
A method for predicting the risk of recurrence and/or death in patients with solid tumors after neoadjuvant therapy.
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2022047243A1
(en)
|
2020-08-27 |
2022-03-03 |
Enosi Life Sciences Corp. |
Methods and compositions to treat autoimmune diseases and cancer
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
MX2023003060A
(en)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Indole derivatives as ras inhibitors in the treatment of cancer.
|
|
MX2023003338A
(en)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Tricyclic pyridones and pyrimidones.
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
JP2024501280A
(en)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
SOS1 inhibitors and their uses
|
|
KR20230146052A
(en)
|
2021-02-12 |
2023-10-18 |
에프. 호프만-라 로슈 아게 |
Bicyclic tetrahydroazepine derivatives for cancer treatment
|
|
CA3211063A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
|
CN118561952A
(en)
|
2021-05-05 |
2024-08-30 |
锐新医药公司 |
RAS inhibitors
|
|
CN117500811A
(en)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
Covalent RAS inhibitors and their uses
|
|
CR20230558A
(en)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
RAS INHIBITORS FOR CANCER TREATMENT
|
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
AU2022315530A1
(en)
|
2021-07-20 |
2024-01-18 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
|
TW202321261A
(en)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
Selective kras inhibitors
|
|
AR127308A1
(en)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
JP2024543912A
(en)
|
2021-11-24 |
2024-11-26 |
ジェネンテック， インコーポレイテッド |
Bicyclic therapeutic compounds and methods of use in the treatment of cancer - Patents.com
|
|
EP4448526A1
(en)
|
2021-12-17 |
2024-10-23 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN118829629A
(en)
|
2022-03-07 |
2024-10-22 |
美国安进公司 |
Process for the preparation of 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
JP2025510572A
(en)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
Methods for treating immunorefractory lung cancer
|
|
US20250205233A1
(en)
|
2022-03-31 |
2025-06-26 |
Astrazeneca Ab |
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
|
|
CA3246312A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CA3257760A1
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
CN119998298A
(en)
|
2022-06-10 |
2025-05-13 |
锐新医药公司 |
Macrocyclic RAS inhibitors
|
|
MA71241A
(en)
|
2022-06-27 |
2025-04-30 |
Astrazeneca Ab |
COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN119604530A
(en)
|
2022-07-19 |
2025-03-11 |
基因泰克公司 |
Administration of Therapeutic Antibodies Using Anti-FCRH5/Anti-CD3 Bispecific Antibodies
|
|
JP2025526726A
(en)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Bicyclic Tetrahydroazepine Derivatives
|
|
PE20250876A1
(en)
|
2022-08-11 |
2025-03-28 |
Hoffmann La Roche |
Bicyclic derivatives of tetrahydrothiazepine
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
KR20250038674A
(en)
|
2022-08-11 |
2025-03-19 |
에프. 호프만-라 로슈 아게 |
Bicyclic tetrahydrothiazepine derivatives
|
|
EP4601644A1
(en)
|
2022-10-14 |
2025-08-20 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
JP2025538859A
(en)
|
2022-10-21 |
2025-12-02 |
公益財団法人川崎市産業振興財団 |
Non-adsorbing or super stealth vesicles
|
|
CN121038801A
(en)
|
2022-10-24 |
2025-11-28 |
Ags治疗简易股份公司 |
Extracellular vesicles from microalgae, their biodistribution during intranasal administration, and their uses
|
|
TW202426505A
(en)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
Therapeutic and diagnostic methods for cancer
|
|
TW202434206A
(en)
|
2023-02-17 |
2024-09-01 |
美商伊瑞斯卡公司 |
Kras inhibitors
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AR132338A1
(en)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
RAS INHIBITORS
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
TW202448897A
(en)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
CN121100123A
(en)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Crystalline form of Ras inhibitors
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202504641A
(en)
|
2023-06-08 |
2025-02-01 |
美商建南德克公司 |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
TW202530228A
(en)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ras inhibitors
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025176843A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|